



September 1, 2013

## **ViperGen presents first discovery of small molecule IL-17A antagonists**

**Copenhagen, Denmark, September 1, 2013 - - ViperGen ApS today announced that the first report on the discovery of the first small molecule IL-17A antagonists will be presented at the Protein-Protein Interaction Conference being held October 23-25, 2013 in San Diego, CA.**

“Our data demonstrate that ViperGen’s two 2<sup>nd</sup> generation technologies, YoctoReactor® and Binder Trap Enrichment®, for small molecule drug discovery, rapidly and seamlessly identify novel and potent hit series for even “hard to drug” targets, including protein-protein interactions like IL-17/IL-17R” said Dr. Nils Hansen, CEO of ViperGen ApS. “IL-17 is a clinically validated target implicated in multiple inflammatory and autoimmune diseases. Discovery of small molecule (MW<500 Da) antagonist has been limited due to technological hurdles and has only been addressed to date with larger molecules, such as biologics and macrocycles. ViperGen has identified more than 800 primary hits, constituting 3 hit series with clear instant structure activity relationships, which may accelerate the hit-to-lead transition and the following lead optimization process. Hits were identified having nanomolar potencies, MW < 500 Da, and cLogP ~2.5, thus providing promising starting points for developing orally bioavailable therapeutics

### **Presentation:**

‘Discovery of the first small molecule IL-17 antagonists’, Nils Hansen, Ph.D. – Chief Executive Officer, ViperGen ApS, Thursday, October 24, 2013, 9:40 am, Session: Protein-Protein Interactions as Drug Targets

### **About ViperGen ApS**

ViperGen is dedicated to small molecule drug discovery using DNA-encoded chemical libraries.

ViperGen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.

ViperGen’s two 2<sup>nd</sup> generation technology platforms - The YoctoReactor® for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment® for screening of such libraries - are designed to deliver high fidelity drug discovery.

For further details about ViperGen and the YoctoReactor®/ Binder Trap Enrichment® drug discovery technology platforms please contact:

#### **ViperGen ApS**

Nils Hansen, CEO

Phone: +45 2523 6680

[nha@vipergen.com](mailto:nha@vipergen.com)